• Publications
  • Influence
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound
Objective: To assess the incidence of a hyperechogenic substantia nigra (SN) by transcranial sonography (TCS) in healthy people and to evaluate whether an enlarged hyperechogenic SN area isExpand
  • 318
  • 17
Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease
Summary.In idiopathic Parkinson’s disease (PD), a tremor-dominant type (TDT), an akinetic-rigid type (ART), and a mixed type (MT) are distinguished. We compared cerebral [I-123]FP-CIT SPECT in the PDExpand
  • 138
  • 15
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
Summary.NT 201 is a new development of Botulinum Toxin Type A free of complexing proteins. In this double-blind Phase III trial, we compared the efficacy and safety of NT 201 and BOTOX® in patientsExpand
  • 214
  • 11
Early diagnosis of Parkinson’s disease
The clinical methods of olfactory testing and color discrimination as well as apparative methods such as transcranial ultrasound, dopamine transporter imaging and MIBG scintigraphy reveal a highExpand
  • 132
  • 10
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
A new botulinum toxin type A free of complexing proteins (NT 201) was compared with BOTOX in patients with cervical dystonia by means of a double-blind noninferiority trial. Four hundred sixty-threeExpand
  • 219
  • 6
Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It isExpand
  • 103
  • 6
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey
To document the current practice in relation with the treatment of patients with upper limb spasticity with botulinum toxin type A to inform future research in this area. We designed anExpand
  • 68
  • 6
Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease.
Hyperechogenic signal of substantia nigra (SN) in transcranial sonography (TCS) and reduced striatal uptake in FP-CIT SPECT are common findings in idiopathic Parkinson's disease (PD). But so far itExpand
  • 122
  • 5
FP‐CIT and MIBG scintigraphy in early Parkinson's disease
Methods provided by nuclear medicine may be helpful in diagnosis of Parkinson's disease (PD). For that purpose, the sensitivity of iodine‐123 metaiodobenzylguanidine ([123I]MIBG) scintigraphy andExpand
  • 110
  • 5
Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment?
A significant percentage of patients suffering from a stroke involving motor-relevant central nervous system regions will develop a spastic movement disorder. Hyperactivity of different muscleExpand
  • 67
  • 5
...
1
2
3
4
5
...